Agnieszka Potęga, PhD 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Department of Pharmaceutical Technology.

Slides:



Advertisements
Similar presentations
Electrochemistry upfront MS
Advertisements

SITES DRUG BIOTRANSFORMATION
Chemistry Dept, UCONN Identification of Drug Metabolites via Mass Spectrometry Besnik Bajrami Chem 395.
Improvements in Mass Spectrometry for Life Science Research – Does Agilent Have the Answer? Ashley Sage PhD.
Biotransformation Xenobiotic metabolism
Determining Estrogenicity of a Cytochrome P450- dependent metabolite of 3,3’-diindolylmethane (DIM) Rachel O’Neal Susan Tilton Dr. David Williams Marine.
Drug metabolism Refers to enzyme-mediated biotransformations (detoxication) that alter the pharmacological activity of both endogenous and exogenous compounds.
DISTRIBUTION The body is a container in which a drug is distributed by blood (different flow to different organs) - but the body is not homogeneous. Factors.
3. Metabolism Many xenobiotics undergo chemical transformation (biotransformation; metabolism) when introduced into biologic systems like the human body.
Microarrays: Tools for Proteomics
1.) fate of xenobiotic -- central role of metabolism Uptake/Transport > Metabolism > Excretion Or Storage 2.) xenobiotic converted.
Metabolism of Xenobiotics I. General Overview Aug 25, 2011 L.M. Ball Rosenau 158 ENVR/TOXC 442 Fall 2011.
Investigation of Oxidative and Conjugative Metabolism Reactions with Liquid Chromatography / Accurate Mass High Resolution Mass Spectrometry Maciej Bromirski.
Phase-II Drug Metabolism
Unique Selling Points (USP) ROXY and Accessories Antec BV Zoeterwoude, The Netherlands 1.
Drug Detoxification Dr. Howaida Supervised by : Prepared by:
Metabolism of Xenobiotics
Drug Metabolism Overview Dr. Arthur Roberts 1. Where to Find Information eLC – most up to date – correct errors 2.
Drug metabolism Prof. M. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General pharmacology.
Biotransformation Xenobiotic metabolism “Essentials of Toxicology” by Klaassen Curtis D. and Watkins John B Chapter 6.
Pharmacokinetics: Bioavailability Asmah Nasser, M.D.
Metabolism - Biotransformation Supplementary readings: Casarett and Doull,Chapter 6 Timbrell, Chapters 4 and 5.
Metabolism Chemical transformaion of xenobiotics Occurs in mostly in liver (enzymatic prosesses) Convertion into more hydrophil. subst. - excretion urine.
Drug bioactivation predicting enzyme based biosensor
Biochemical functions of liver
Using Spotfire DecisionSite to Realize the Full Value of High-Throughput Screening ADME Data Eric Milgram Pfizer Global Research & Development – La Jolla.
Phase II: Conjugation Synthetic reaction of a xenobiotic (or of a Phase I metabolite of a xenobiotic) with an endogenous substance Results in introduction.
Drug Metabolism and Prodrugs
Biomarkers Biomarkers - markers in biological systems with a sufficently long half-life which allow location where in the biological system change occur.
1 Pharmacology Pharmacokinetics –Absorption –Distribution –Biotransformation (metabolism) –Excretion Pharmacodynamics –Receptor binding –Signal transduction.
Phase II: Conjugation Synthetic reaction of a xenobiotic (or of a Phase I metabolite of a xenobiotic) with an endogenous substance Results in introduction.
Section 1, Lecture 4 Phase I reactions-oxidative occur in the endoplasmic reticulum of liver (microsomal fractions) - catalyzed by the microsomal.
LIVER PHYSIOLOGY & PATHOPHYSIOLOGY TILLY ADAMSON HELEN TURNBULL-ROSS.
Prof. Hanan Hagar Dr.Abdul latif Mahesar Pharmacology Department.
CYP Biotransformations
1 drug molecule Highly lipophyllic lipophilic polar hydrophylic accumulation (fatty tissues) phase I polar phase IIbioinactivation conjugation hydrophylic.
Pharmacology Department
LIVER CLINICAL BIOCHEMISTRY
Drug Metabolism and Prodrugs
Metabolic Stability Lee, Sang-Hwi. -2- Overview Metabolism is the enzymatic modification of compounds to increase clearance. It is a determinant.
Detoxification Chemicals entering body (mostly via food) must pass through liver.
Evaluation of skin metabolism of Benzo(a)pyrene : ex vivo skin explant model validation C. Jacques, E.L. Jamin, E. Perdu, S. Bessou-Touya, D. Zalko and.
Biotransformation of xenobiotics and endogenous toxins in the liver: microsomal oxidation, cytochrome Р-450.
Metabolism Chemical transformaion of xenobiotics Occurs in mostly in liver (enzymatic prosesses) Convertion into more hydrophil. subst. - excretion urine.
Pharmacology I BMS 242 Lecture 4 Pharmacokienetic Principles (3&4): Drug Metabolism and Excretion [Elimination] Dr. Aya M. Serry 2016.
Emmanuelle Germain, Joelle Chevalier, Marlène Steib, Marie-Hélène Siess* and Caroline Teyssier* Institut National de la Recherche Agronomique / ENSBANA,
Medicinal Chemistry Lecture Drug Metabolism Lectures 11 & 13 Chemical Delivery Systems Joseph O. Oweta | PHS 2201.
CYTOCHROMES M.Prasad Naidu MSc Medical Biochemistry,
11 Simulating of in vivo metabolism taking into account detoxification logics.
In-vitro metabolite profiling of by LC-MS/MS Tejaswini Kailas Jadhav MS (Pharmaceutical Analysis) NIPER-A.
Xenobiotic metabolites The organism removes xenobiotics by xenobiotic metabolism, consisting of deactivation/activation and excretion of xenobiotics, which.
In Vitro Metabolism and Prediction of Drug-Drug Interaction of the Calcimimetic Agent Cinacalcet HCl Manoj Bajpai, Joel Esmay, Victor Chi, Mike Hayashi,
METABOLISM / BIOTRANSFORMATION of TOXICANTS.
Chapter 5 Drug Metabolism
Detoxification by the Liver
Metabolism - Biotransformation
Mimicking Oxidative Metabolism “OxMet” using ROXY EC System
Metabolism & Detoxification
Metabolism of drugs and xenobiotics
Environmental Degradation of Pharmaceuticals and Pollutants using EC/MS ASMS 2015 St. Louis, MO, USA.
Drug Elimination Drug elimination consists of 2 processes
Induction Increased transcription Increased protein synthesis
Metabolism of porphyrins: metabolism of bile pigments, biochemistry of jaundices. 1.
Phase-II Drug Metabolism Pharmaceutical Medicinal Chemistry-I
Phase-I Drug Metabolism Pharmaceutical Medicinal Chemistry-I
Xenobiotic or Drug Metabolism
Ovanes Mekenyan, Milen Todorov, Ksenia Gerova
Drug Detoxification Dr. Howaida Supervised by : Prepared by:
Pharmaceutical Stability Testing using Electrochemistry-MS
Electrochemical Synthesis of Metabolites, Degradants, Reference Materials ASMS 2018 San Diego, CA, USA.
Presentation transcript:

Agnieszka Potęga, PhD 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Department of Pharmaceutical Technology and Biochemistry Laboratory of Chemistry and Biochemistry of Anticancer Drugs Chemical Faculty Electrochemical simulation: a powerful tool for the elucidation and study of drug metabolism reactions.

Conventional approaches in drug metabolism studies. Electrochemistry/mass spectrometry for metabolite generation and identification. The selected results of own studies. Keywords: antitumor compounds, liver cell microsomes, cytochrome P450, oxidative drug metabolism, electrochemical simulation, mass spectrometry 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Electrochemical simulation: a powerful tool for the elucidation and study of drug metabolism reactions.

Degradation pathway of xenobiotics Phase-I metabolism (activation): oxidation reactions (often catalysed by enzymes of the cytochrome P450 superfamily), reduction and hydrolysis reactions (intermediate metabolites – more polar, less lipophilic) Phase-II metabolism (detoxification): enzyme-catalysed conjugation reactions with small polar endogenous compounds like tripeptide glutathione, glucuronic acid, sulfate, or glycine (metabolites – polar, water-soluble, easily excreted from the human body in urine or bile) Xenobiotics (nonpolar, lipophilic) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014

Conventional approaches in drug metabolism studies liver cell microsomes laboratory animals In vivo and in vitro methods, using laboratory animals, isolated liver cells (hepatocytes) or microsomes, containing active enzymes, i.a. the cytochrome P450 system. 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014

Conventional approaches in drug metabolism studies In vivo and in vitro methods, using laboratory animals, isolated liver cells (hepatocytes) or microsomes, containing active enzymes, i.a. the cytochrome P450 system.  Laborious and time consuming.  Metabolites may form adducts with the cell matrix, hence isolation and identification of reactive metabolites is hampered.  Variations in the expression of cytochrome P450 isoforms in each organism have to be taken into account. 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Distribution of drug metabolising enzymes in liver cells. CYP, cytochrome P450 monooxygenase; FMO, flavin-dependent monooxygenase; UGT, UDP-glucuronosyl transferase; GST, glutathione transferase; SULT, sulfotransferase; NAT, N-acetyltransferase. Microsomes: CYPs FMOs UGTs GSTs Cytosol: dehydrogenases oxidases SULTs GSTs NATs S9 Hepatocyte

Electrochemistry/mass spectrometry (EC/MS) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 EC/MS – a powerful platform to simulate various oxidation and reduction processes.  Electrochemical cell for the simulation of the oxidative and reductive phase-I metabolism.  High potential for screening of single target compounds in phase-II metabolomics studies.  Fast method for direct identification of reactive metabolites because of the absence of biological matrices.  Delivers a redox fingerprint of a (drug) molecule, close to metabolic profile, in a very short time.

Electrochemistry/mass spectrometry (EC/MS) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 EC/MS – a powerful platform to simulate various oxidation and reduction processes.  Electrochemical cell for the simulation of the oxidative and reductive phase-I metabolism.  High potential for screening of single target compounds in phase-II metabolomics studies.  Fast method for direct identification of reactive metabolites because of the absence of biological matrices.  Delivers a redox fingerprint of a (drug) molecule, close to metabolic profile, in a very short time. Instrumental set-up of EC system dual syringe infusion pump mass spectrometer (MS) potentiostat electrochemical thin-layer cell (EC) – reactor cell  high speed  simplicity  ease of automation  low-cost instrumentation

Electrochemistry/mass spectrometry (EC/MS) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 EC/MS – a powerful platform to simulate various oxidation and reduction processes.  Electrochemical cell for the simulation of the oxidative and reductive phase-I metabolism.  High potential for screening of single target compounds in phase-II metabolomics studies.  Fast method for direct identification of reactive metabolites because of the absence of biological matrices.  Delivers a redox fingerprint of a (drug) molecule, close to metabolic profile, in a very short time. Simulation in an amperometric thin-layer cell  low adsorption on the electrode surface  easily exchangeable working electrode Pd/H 2

Electrochemistry/mass spectrometry (EC/MS) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Electrochemical reaction ΔEΔE EC/MS – a powerful platform to simulate various oxidation and reduction processes.  Electrochemical cell for the simulation of the oxidative and reductive phase-I metabolism.  High potential for screening of single target compounds in phase-II metabolomics studies.  Fast method for direct identification of reactive metabolites because of the absence of biological matrices.  Delivers a redox fingerprint of a (drug) molecule, close to metabolic profile, in a very short time.

Electrochemistry/mass spectrometry (EC/MS) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Set-ups of the most common approaches for the simulation of drug metabolism reactions EC/MS – a powerful platform to simulate various oxidation and reduction processes.  Electrochemical cell for the simulation of the oxidative and reductive phase-I metabolism.  High potential for screening of single target compounds in phase-II metabolomics studies.  Fast method for direct identification of reactive metabolites because of the absence of biological matrices.  Delivers a redox fingerprint of a (drug) molecule, close to metabolic profile, in a very short time. Adapted from Baumann et al., Expert Opin Drug Metab Toxicol, 2010 MS detector EC cell Potentiostat Drug A EC/MS system LC column Potentiostat EC cellDrug MS detector B EC/LC/MS system

Electrochemistry/mass spectrometry (EC/MS) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Typical phase I reactions and the possibility for their electrochemical simulation Typical reactions catalysed by cytochrome P450Simulation by electrochemistry Allylic and aliphatic hydroxylation Succesfully mimicked at high potentials Benzylic hydroxylation Sucessfully mimicked, but only in low yields Desalkylation of aminesReadily mimicked Desalkylation of ethers and thioethers Ethers: possible Thioethers: not mimicked Hydroxylation of aromaticsPossible Epoxide formationNot mimicked Oxidation of heteroatoms (N, S) Sucessfully mimicked (but N-oxide formation only in low yields) Alcohol and aldehyde oxidationNot mimicked DehydrogenationReadily mimicked Adapted from Lohmann et al., LC-GC Europe, Jan 2010 EC/MS – a powerful platform to simulate various oxidation and reduction processes.  Electrochemical cell for the simulation of the oxidative and reductive phase-I metabolism.  High potential for screening of single target compounds in phase-II metabolomics studies.  Fast method for direct identification of reactive metabolites because of the absence of biological matrices.  Delivers a redox fingerprint of a (drug) molecule, close to metabolic profile, in a very short time.

Electrochemistry/mass spectrometry (EC/MS) 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Typical phase I reactions and the possibility for their electrochemical simulation Typical reactions catalysed by cytochrome P450Simulation by electrochemistry Allylic and aliphatic hydroxylation Succesfully mimicked at high potentials Benzylic hydroxylation Sucessfully mimicked, but only in low yields Desalkylation of aminesReadily mimicked Desalkylation of ethers and thioethers Ethers: possible Thioethers: not mimicked Hydroxylation of aromaticsPossible Epoxide formationNot mimicked Oxidation of heteroatoms (N, S) Sucessfully mimicked (but N-oxide formation only in low yields) Alcohol and aldehyde oxidationNot mimicked DehydrogenationReadily mimicked Adapted from Lohmann et al., LC-GC Europe, Jan 2010 EC/MS – a powerful platform to simulate various oxidation and reduction processes.  Electrochemical cell for the simulation of the oxidative and reductive phase-I metabolism.  High potential for screening of single target compounds in phase-II metabolomics studies.  Fast method for direct identification of reactive metabolites because of the absence of biological matrices.  Delivers a redox fingerprint of a (drug) molecule, close to metabolic profile, in a very short time.

RESEARCH OBJECTIVES 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Financial support by the National Science Centre (Poland) (project SONATA No 2012/07/D/NZ7/03395)  Investigation phase-I metabolism of the model antitumor acridine derivatives, C-1311 and C-1748, under electrochemical conditions coupled to mass spectrometry (EC/MS).  Comparison the results obtained by EC/MS with conventional in vitro microsomal approach.

5-diethyloaminoethyloamino-8-hydroxyimidazoacridinone C (2’-hydroxyethyloamino)-4-methylo-1-nitroacridine C rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014  inhibitor of both topoisomerases and certain receptor kinases, including FMS-like tyrosine kinase FLT3 (Chau et al., 2006; Skwarska et al., 2010)  activity against advanced solid tumors under phase I and II of clinical trials, also tested for the treatment of autoimmune diseases (Capizzi et al., 2008; Isambert et al., 2010)  strong cytotoxic activity against colon cancer cel lines (HCT8 and HT29) (Augustin et al., 2010) and high antitumor activity against several prostate (LnCaP, JCA, PC3, TSU) and colon carcinoma xenografts (HCT8) in nude mice (Chen et al., 2002; Tadi et al., 2007)  low mutagenic potential and slight myelosuppressive properties (Narayanan et al., 2005)  different structures  various metabolic pathways THE STUDIED COMPOUNDS

Enzymatic transformations of C-1311 and C rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Figure: Linear chromatograms of the reaction mictures containing 0.05 mM (A) C-1311 (B) C-1748, 1 mM NADPH and 2 mg/mL microsomal (S9) fraction of liver cells in sodium phosphate buffer (pH7.4).  RP-HPLC-DAD/ESI-MS analysis Table: Gradient profile utilized for all HPLC analyses. A: 50 mM aqueous ammonium formate buffer (pH 3.4) + 5% methanol for HPLC B: Methanol for HPLC + 5% H 2 O AB

Electrochemical simulation of C-1311 metabolism 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Figure: C-1311 abundance vs. electrosynthesis time.

Electrochemical simulation of C-1311 metabolism 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Figure: The proposed chemical structures of C-1311 metabolites obtained in enzymatic (—) and electrochemical (—) system ([ ]* – intermediate product).

Electrochemical simulation of C-1748 metabolism 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Figure: C-1748 abundance vs. electrosynthesis time.

Electrochemical simulation of C-1748 metabolism Figure: The proposed chemical structures of C-1748 metabolites obtained in enzymatic (—) and electrochemical (—) system. 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014

Electrochemical system is very well-suited for the simulation of the oxidative and reductive metabolism of antitumor acridine derivatives. SUMMARY & CONCLUSIONS  Electrochemical conversion of C-1311 and C-1748 into phase-I metabolites was successfully achieved. Two main metabolic products of C-1311 (side chain degradation products) and three products of C-1748 were detected both in the conventional enzymatic approach and in the electrochemical simulation.  An additional product of C-1748 (1-aminoacridone) was found only in the electrochemical simulation. 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014

SUMMARY & CONCLUSIONS 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 The purely instrumental approach, based on electrochemical conversion, is a feasible alternative to the conventional microsomal studies.

Application areas of electrochemistry/mass spectrometry coupling EC/MS reduction of disulfide bridges metabolite synthesis MS signal amplification cleaving of peptide bonds oxidative DNA demage metabolism studies stability studies active substance- protein binding oxidative protein marking 3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014

3 rd INTERNATIONAL SUMMIT ON TOXICOLOGY & APPLIED PHARMACOLOGY Chicago, USA, October 20 – 22, 2014 Electrochemical simulation: a powerful tool for the elucidation and study of drug metabolism reactions. 1 Department of Pharmaceutical Technology and Biochemistry 2 Department of Analytical Chemistry Chemical Faculty Zofia Mazerska 1, Assoc Prof Weronika Hewelt-Belka 2, MSc Olga Siewruk 1 Katarzyna Zapała 1

Thank you for your attention!